[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552940":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":20,"id":52,"slug":20,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Children's Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"long term follow up","EXPERIMENTAL","All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.",[13],"Genetic: CS-101",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"GENETIC","CS-101","Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Xiaowen Zhai, M.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86-021-64931126","zhaixiaowendy@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Zifeng Li, M.S.","+86-13920704768","zfli18@fudan.edu.cn",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Shanghai","Shanghai Municipality","201102","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100552940",false,"NCT06479616","A Long-term Follow-up Study in Participants Who Received CS-101","A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation","Inclusion Criteria:\n\n* Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form\n* Participants must have received CS-101 infusion in last IIT study\n\nExclusion Criteria:\n\n* There are no exclusion criteria","ALL","3 Years","17 Years",{"count":62,"type":63},5,"ESTIMATED","INTERVENTIONAL",[66],"NA","This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)",[69],"Beta-Thalassemia","2025-09-04",{"date":72,"type":73},"2025-09-10","ACTUAL",{"date":75,"type":73},"2024-06-18",{"date":77,"type":63},"2027-06",{"name":5,"class":6},1]